| 1 |
中国肝移植注册中心. 2018年中国肝脏移植医疗质量报告[R]. 杭州：中国肝移植注册中心，2019.
|
| 2 |
Organ Procurement and Transplantation Network. View data reports[DB/OL]. [2019-07-25].
URL
|
| 3 |
Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrino, 2019, 15(3): 172-188.
|
| 4 |
Gojowy D, Adamczak M, Dudzicz S, et al. High frequency of arterial hypertension in patients after liver transplantation[J]. Transplant Proc, 2016, 48(5): 1721-1724.
|
| 5 |
中华医学会器官移植学分会. 中国实体器官移植受者血脂管理规范(2019版)[J]. 器官移植，2019, 10(2): 101-111.
|
| 6 |
Neal DA, Tom BD, Gimson AE, et al. Hyperuricemia, gout, and renal function after liver transplantation[J]. Transplantation, 2001, 72(10): 1689-1691.
|
| 7 |
Longenecker JC, Waheed S, Bandak G, et al. Hyperuricemia after orthotopic liver transplantation: divergent associations with progression of renal disease, incident end-stage renal disease, and mortality[J]. BMC Nephrol, 2017, 18(1): 103.
|
| 8 |
陈池义，蒋文涛，张骊，等. 成人肝移植后远期高尿酸血症及肾损害的治疗27例[J]. 中华器官移植杂志，2016, 37(7): 411-414.
|
| 9 |
饶伟萍，牛玉坚，王宏宇，等. 肝移植后高尿酸血症的发生率和相关危险因素分析：单中心回顾性研究[J]. 中华内分泌外科杂志，2015, (6): 493-496.
|
| 10 |
Rezende Anastácio L, García Ferreira L, Costa Liboredo J, et al. Overweight, obesity and weight gain up to three years after liver transplantation[J]. Nutr Hosp, 2012, 27(4): 1351-1356.
|
| 11 |
Sundaram SS, Alonso EM, Zeitler P, et al. Obesity after pediatric liver transplantation: prevalence and risk factors[J]. J Pediatr Gastroenterol Nutr, 2012, 55(6): 657-662.
|
| 12 |
Davis BC, Shadab Siddiqui M. Liver transplantation: the role of metabolic syndrome[J]. Curr Treat Options Gastroenterol, 2017, 15(2): 316-331.
|
| 13 |
李新宇，黄磊，朱继业，等. 肝移植术后生存10年及以上患者远期并发症随访分析[J]. 中华全科医师杂志，2019, 18(4): 347-351.
|
| 14 |
Barnard A, Konyn P, Saab S, et al. Metabolic complications in liver transplant recipients[J]. World J Gastroenterol, 2016, 22(28): 6416-6423.
|
| 15 |
Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transpl, 2013, 19(1): 3-26.
|
| 16 |
Parekh J, Corley DA, Feng S. Diabetes, hypertension and hyperlipidemia: prevalence over time and impact on long-term survival after liver transplantation[J]. Am J Transplant, 2012, 12(8): 2181-2187.
|
| 17 |
李新宇，朱继业，黄磊，等. 肝移植术后代谢综合征及危险因素分析[J]. 中华普通外科杂志，2012, 27(1): 8-11.
|
| 18 |
Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2017 Annual Data Report: Liver[J]. Am J Transplant, 2019, 19(Suppl 2): 184-283.
|
| 19 |
Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management[J]. J Hepatol, 2010, 53(1): 199-206.
|
| 20 |
Laish I, Braun M, Mor E, et al. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events[J]. Liver Transpl, 2011, 17(1): 15-22.
|
| 21 |
De Simone P, Carrai P, Coletti L, et al. Everolimus vs mycophenolate mofetil in combination with tacrolimus: A propensity score-matched analysis in liver transplantation[J]. Transplant Proc, 2018, 50(10): 3615-3620.
|
| 22 |
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients[J]. Am J Transplant, 2009, 9(Suppl 3): S1-S155.
|
| 23 |
Neuberger JM, Bechstein WO, Kuypers DR, et al. Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: A guidance report and clinical checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group[J]. Transplantation, 2017, 101(4S Suppl 2): S1-S56.
|
| 24 |
American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2019[J]. Diabetes care, 2019, 42(Suppl 1): S13-S28.
|
| 25 |
American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2018 [J]. Diabetes care, 2018, 41(Suppl 1): S13-S27.
|
| 26 |
Charlton M, Levitsky J, Aqel B, et al. International Liver Transplantation Society consensus statement on immunosuppression in liver transplant recipients[J]. Transplantation, 2018, 102(5): 727-743.
|
| 27 |
中国医师协会器官移植医师分会，中华医学会外科学分会器官移植学组，中华医学会器官移植学分会肝移植学组. 中国肝移植受者代谢病管理专家共识(2015版) [J/CD]. 中华移植杂志：电子版，2015, 9(3): 103-107.
|
| 28 |
Grancini V, Resi V, Palmieri E, et al. Management of diabetes mellitus in patients undergoing liver transplantation[J]. Pharmacol Res, 2019, 141: 556-573.
|
| 29 |
Song JL, Li M, Yan LN, et al. Higher tacrolimus blood concentration is related to increased risk of post-transplantation diabetes mellitus after living donor liver transplantation[J]. Int J Surg, 2018, 51: 17-23.
|
| 30 |
Li DW, Lu TF, Hua XW, et al. Risk factors for new onset diabetes mellitus after liver transplantation: A meta-analysis[J]. World J Gastroenterol, 2015, 21(20): 6329-6340.
|
| 31 |
Yagi S, Kaido T, Iida T, et al. New-onset diabetes mellitus after living-donor liver transplantation: association with graft synthetic function[J]. Surg Today, 2017, 47(6): 733-742.
|
| 32 |
Cen C, Fang HX, Yu SF, et al. Association between ADIPOQ gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2017, 16(6): 602-609.
|
| 33 |
Zhang T, Liu Y, Hu Y, et al. Association of donor and recipient SUMO4 rs237025 genetic variant with new-onset diabetes mellitus after liver transplantation in a Chinese population[J]. Gene, 2017, 627: 428-433.
|
| 34 |
Gillis KA, Patel RK, Jardine AG. Cardiovascular complications after transplantation: treatment options in solid organ recipients[J]. Transplant Rev (Orlando), 2014, 28(2): 47-55.
|
| 35 |
Kato T, Gaynor JJ, Yoshida H, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year[J]. Transplantation, 2007, 84(7): 829-835.
|
| 36 |
Kim YK, Lee KW, Kim SH, et al. Early steroid withdrawal regimen prevents new-onset diabetes mellitus in old-age recipients after living donor liver transplantation[J]. World J Surg, 2012, 36(10): 2443-2448.
|
| 37 |
Lorho R, Hardwigsen J, Dumortier J, et al. Regression of new-onset diabetes mellitus after conversion from tacrolimus to cyclosporine in liver transplant patients: results of a pilot study[J]. Clin Res Hepatol Gastroenterol, 2011, 35(6-7): 482-488.
|
| 38 |
Herrero JI, Quiroga J, Sangro B, et al. Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus[J]. Transplant Proc, 2003, 35(5): 1877-1879.
|
| 39 |
American Diabetes Association. Standards of medical care in diabetes-2014[J]. Diabetes care, 2014, 37(Suppl 1): S14-S80.
|
| 40 |
Jenssen T, Hartmann A. Prevention and management of transplant-associated diabetes[J]. Expert Opin Pharmacother, 2011, 12(17): 2641-2655.
|
| 41 |
中华医学会器官移植学分会. 中国移植后糖尿病诊疗技术规范(2019版)[J]. 器官移植，2019, 10(1): 1-9.
|
| 42 |
Neal DA, Brown MJ, Wilkinson IB, et al. Mechanisms of hypertension after liver transplantation[J]. Transplantation, 2005, 79(8): 935-940.
|
| 43 |
Fujinaga K, Usui M, Yamamoto N, et al. Hypertension and hepatitis C virus infection are strong risk factors for developing late renal dysfunction after living donor liver transplantation: significance of renal biopsy[J]. Transplantation proceedings, 2014, 46(3): 804-810.
|
| 44 |
Tong MS, Chai HT, Liu WH, et al. Prevalence of hypertension after living-donor liver transplantation: a prospective study[J]. Transplant Proc, 2015, 47(2): 445-450.
|
| 45 |
中华医学会器官移植学分会. 中国实体器官移植术后高血压诊疗规范(2019版)[J]. 器官移植，2019, 10(2): 112-121.
|
| 46 |
Thoefner LB, Rostved AA, Pommergaard HC, et al. Risk factors for metabolic syndrome after liver transplantation: A systematic review and meta-analysis[J]. Transplant Rev (Orlando), 2018, 32(1): 69-77.
|
| 47 |
García-Pajares F, Peñas-Herrero I, Sánchez-Ocaña R, et al. Metabolic syndrome after liver transplantation: Five-year prevalence and risk factors[J]. Transplant Proc, 2016, 48(9): 3010-3012.
|
| 48 |
Anastácio LR, Ribeiro Hde S, Ferreira LG, et al. Incidence and risk factors for diabetes, hypertension and obesity after liver transplantation[J]. Nutr Hosp, 2013, 28(3): 643-648.
|
| 49 |
Rabkin JM, Rosen HR, Corless CL, et al. Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients[J]. Transplant Proc, 2002, 34(5): 1557-1558.
|
| 50 |
Guckelberger O. Long-term medical comorbidities and their management: hypertension/cardiovascular disease[J]. Liver Transpl, 2009, 15(Suppl 2): S75-S78.
|
| 51 |
D′Avola D, Cuervas-Mons V, Martí J, et al. Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil[J]. Liver Transpl, 2017, 23(4): 498-509.
|
| 52 |
Gonwa T, Mendez R, Yang HC, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months[J]. Transplantation, 2003, 75(8): 1213-1220.
|
| 53 |
Wei Q, Gao F, Zhuang R, et al. A national report from China Liver Transplant Registry: steroid avoidance after liver transplantation for hepatocellular carcinoma[J]. Chin J Cancer Res, 2017, 29(5): 426-437.
|
| 54 |
Barnard A, Konyn P, Saab S. Medical management of metabolic complications of liver transplant Recipients[J]. Gastroenterol Hepatol (N Y), 2016, 12(10): 601-608.
|
| 55 |
Sohn AJ, Jeon H, Ahn J. Primary care of the liver transplant recipient[J]. Prim Care, 2011, 38(3): 499-514; ix.
|
| 56 |
Warden BA, Duell PB. Management of dyslipidemia in adult solid organ transplant recipients[J]. J Clin Lipidol, 2019, 13(2): 231-245.
|
| 57 |
Orlando G, Baiocchi L, Cardillo A, et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension[J]. Liver Transpl, 2007, 13(1): 46-54.
|
| 58 |
沈卫峰. 难治性心血管系统疾病[M]. 上海：上海科学技术出版社，2007.
|
| 59 |
中华医学会器官移植学分会. 中国肾移植术后高尿酸血症诊疗技术规范(2019版)[J]. 器官移植，2019, 10(1): 10-5.
|
| 60 |
Laine J, Holmberg C. Mechanisms of hyperuricemia in cyclosporine-treated renal transplanted children[J]. Nephron, 1996, 74(2): 318-323.
|
| 61 |
Tumgor G, Arikan C, Kilic M, et al. Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children[J]. Pediatr Transplant, 2006, 10(6): 665-668.
|
| 62 |
Malheiro J, Almeida M, Fonseca I, et al. Hyperuricemia in adult renal allograft recipients: prevalence and predictors[J]. Transplant Proc, 2012, 44(8): 2369-2372.
|
| 63 |
Kaynar K, Ersoz S, Aliyazicioglu R, et al. Is there any way to protect from tacrolimus-induced renal and pancreas injury？[J]. Clin Transplant, 2012, 26(5): 722-728.
|
| 64 |
Kanbay M, Akcay A, Huddam B, et al. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients[J]. Transplant Proc, 2005, 37(7): 3119-3120.
|
| 65 |
中国医师协会肾脏内科医师分会. 中国肾脏疾病高尿酸血症诊治的实践指南(2017版)[J]. 中华医学杂志，2017, 97(25): 1927-1936.
|
| 66 |
Moreno Planas JM, Cuervas-Mons Martinez V, Rubio Gonzalez E, et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation[J]. Am J Transplant, 2004, 4(10): 1650-1655.
|
| 67 |
Klintmalm GB, Nashan B. The role of mTOR inhibitors in liver transplantation: Reviewing the evidence[J]. J Transplant, 2014: 845438.
|
| 68 |
Sofue T, Inui M, Hara T, et al. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients[J]. Drug Des Devel Ther, 2014, 8: 245-253.
|
| 69 |
Beckmann S, Denhaerynck K, Stampf S, et al. New-onset obesity after liver transplantation-outcomes and risk factors: the Swiss Transplant Cohort Study[J]. Transpl Int, 2018, 31(11): 1254-1267.
|
| 70 |
Richards J, Gunson B, Johnson J, et al. Weight gain and obesity after liver transplantation[J]. Transpl Int, 2005, 18(4): 461-466.
|
| 71 |
Saab S, Lalezari D, Pruthi P, et al. The impact of obesity on patient survival in liver transplant recipients: a meta-analysis[J]. Liver Int, 2015, 35(1): 164-170.
|
| 72 |
Spengler EK, O′Leary JG, Te HS, et al. Liver transplantation in the obese cirrhotic patient[J]. Transplantation, 2017, 101(10): 2288-2296.
|
| 73 |
Bray GA, Frühbeck G, Ryan DH, et al. Management of obesity[J]. Lancet, 2016, 387(10031): 1947-1956.
|
| 74 |
Lim LG, Cheng CL, Wee A, et al. Prevalence and clinical associations of posttransplant fatty liver disease[J]. Liver Int, 2007, 27(1): 76-80.
|
| 75 |
Everhart JE, Lombardero M, Lake JR, et al. Weight change and obesity after liver transplantation: incidence and risk factors[J]. Liver Transpl Surg, 1998, 4(4): 285-296.
|
| 76 |
Charlton M, Rinella M, Patel D, et al. Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: Results of a randomized multicenter study[J]. Transplantation, 2017, 101(12): 2873-2882.
|
| 77 |
Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline[J]. J Clin Endocrinol Metab, 2015, 100(2): 342-362.
|
| 78 |
Kopelman PG. Obesity as a medical problem[J]. Nature, 2000, 404(6778): 635-643.
|
| 79 |
Lazzati A, Iannelli A, Schneck AS, et al. Bariatric surgery and liver transplantation: a systematic review a new frontier for bariatric surgery[J]. Obes Surg, 2015, 25(1): 134-142.
|
| 80 |
Ayloo S, Armstrong J, Hurton S, et al. Obesity and liver transplantation[J]. World J Transplant, 2015, 5(3): 95-101.
|
| 81 |
中华医学会内分泌学分会. 高尿酸血症和痛风治疗的中国专家共识[J]. 中华内分泌代谢杂志，2013, 29(11): 913-920.
|
| 82 |
中华医学会内分泌学分会. 中国2型糖尿病合并肥胖综合管理专家共识[J]. 中华糖尿病杂志，2016, 8(11): 662-666.
|